Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma - Quiz - MDSpire

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • By

  • Chunxiao Ni

  • Jiaju Xu

  • Yu Pang

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • by Chunxiao Ni, Jiaju Xu, Yu Pang

  • June 10, 2026

Related Content

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors